Status and phase
Conditions
Treatments
About
The aim of this 6-month randomized multi-regional double-blind parallel group placebo-controlled phase 3 study is to assess the efficacy and safety of three different doses of Tigulixostat in gout patients with hyperuricemia.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
350 participants in 4 patient groups, including a placebo group
Loading...
Central trial contact
Younghwan Jang
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal